Academician Zhang Yun: Tongxinluo’s anti-atherosclerosis research results pave the way to health for patients with cardiovascular disease

[ad_1]

“For patients with subclinical atherosclerosis, on the basis of modern conventional treatment, Tongxinluo treatment can delay the progression of carotid intima-media thickness, plaque area and vascular remodeling, and has good safety profile.” February 24 On the 20th, at the 20th International Congress of Collateral Diseases, Academician Zhang Yun gave an academic report titled “Twenty Years of Research on Tongxinluo’s Anti-atherosclerosis” and introduced the research on Tongxinluo that he has led for more than 20 years. Scientific research results in the treatment of atherosclerotic cardiovascular disease have confirmed that Tongxinluo has good efficacy in stabilizing vulnerable plaques, inhibiting endothelial damage and apoptosis, and promoting angiogenesis.

Academician Zhang Yun gave an academic report entitled “Twenty Years of Research on Tongxinluo’s Anti-atherosclerosis” at the conference.

Atherosclerosis is the initiating factor of cardiovascular and cerebrovascular diseases and seriously threatens human health. Epidemiological data show that despite active intervention and treatment of atherosclerosis, more than half of atherosclerosis patients still progress. In order to solve this international medical problem, Academician Zhang Yun’s team has conducted more than 20 years of research and exploration on “the clinical efficacy and mechanism of the traditional Chinese medicine Tongxinluo in anti-atherosclerosis.”

Basic research: Tongxinluo can effectively inhibit plaque formation and reduce the risk of plaque rupture

The team’s “fate” with Tongxinluo has been around for a long time. Academician Zhang Yun recalled: “We have been conducting research on Tongxinluo on atherosclerosis for more than 20 years. At that time, we planned to focus on drugs with clear intervention effects on atherosclerosis. Drugs, conduct animal studies and collect some objective evidence. As for traditional Chinese medicine, Tongxinluo was found to have a clear effect in treating coronary heart disease and angina pectoris, so it was selected by the team as a research drug to conduct comparative studies with simvastatin.” After a lot of research by the team, Research work related to Tongxinluo’s anti-atherosclerosis research has achieved remarkable results. In 2009, the research paper on Tongxinluo’s stabilization of vulnerable plaques conducted by Academician Zhang Yun was published in the international authoritative medical journal “American Journal of Physiology”, confirming that Tongxinluo can stabilize vulnerable plaques. Xinluo can effectively inhibit plaque formation and reduce the risk of plaque rupture, thereby reducing the risk of myocardial infarction and cerebral infarction.

The editorial board of the “American Journal of Physiology” commented that Tongxinluo “lit a beacon of hope for high-risk patients who may develop coronary heart disease events in the future!” Academician Zhang Yun pointed out: “The “American Journal of Physiology” is a mainstream magazine in the United States, which has never been the case before. has published research related to traditional Chinese medicine. Starting from this article by Tongxinluo, this journal has opened the door to receive research articles on traditional Chinese medicine. Therefore, our work is not only publishing an article, but also opening up A gateway to America’s mainstream magazines.”

Clinical research: Tongxinluo can inhibit plaque formation and reduce the risk of cardiovascular and cerebrovascular events

In his report, Academician Zhang Yun also focused on the “randomized, double-blind, placebo-controlled, multi-center study of using Tongxinluo to intervene in carotid artery plaque” led by him. This study was jointly conducted with 35 comprehensive top-level hospitals in the country. , 1212 patients with subclinical carotid atherosclerosis were screened out in 18 provinces. Academician Zhang Yun pointed out that this study confirmed that the application of Tongxinluo in the treatment of patients with subclinical arteriosclerosis can safely and effectively reduce the intima-media thickness of the bilateral carotid artery walls, reduce the plaque area, and improve the vascular remodeling index. The carotid artery is the window of the human body’s blood vessels and is integrated with the blood vessels and capillaries everywhere in the human body. This means that Tongxinluo can not only stabilize the plaques in the cardiovascular and cerebrovascular vessels and capillaries, inhibit the formation of plaques, but also reverse the effects of plaques on them. It can significantly reduce the risk of cardiovascular and cerebrovascular events such as angina pectoris, myocardial infarction, and cerebral infarction, and has good safety. The results of this evidence-based research were published in Scientific Reports, a sub-journal of the internationally renowned magazine Nature, in 2019, attracting widespread attention from domestic and foreign academic circles. Ge Junbo, an academician of the Chinese Academy of Sciences, commented that “Academician Zhang Yun has found for us the key to blocking the occurrence and development of atherosclerosis”; Huang Luqi, president of the Chinese Academy of Chinese Medical Sciences and academician of the Chinese Academy of Engineering, published a review in the journal “Pharmacology and Therapeutics” Pointed out that “this experiment shows that Tongxinluo can reduce plaque area and vascular remodeling index without significant side effects” and fully affirmed the study.

Academician Liu Depei pointed out in his on-site comments that a series of studies conducted by Academician Zhang Yun confirmed that Tongxinluo can further inhibit the progression of atherosclerosis on the basis of conventional Western medicine for anti-atherosclerosis, and provide information for the combination of traditional Chinese and Western medicine in the fight against atherosclerosis. solution.

[ad_2]

Source link